Provided by Tiger Trade Technology Pte. Ltd.

Ashland

59.77
+1.121.91%
Post-market: 59.770.00000.00%17:49 EST
Volume:1.52M
Turnover:90.00M
Market Cap:2.74B
PE:-3.25
High:60.27
Open:58.16
Low:57.85
Close:58.65
52wk High:74.57
52wk Low:45.21
Shares:45.76M
Float Shares:41.77M
Volume Ratio:1.30
T/O Rate:3.63%
Dividend:1.64
Dividend Rate:2.74%
EPS(TTM):-18.3696
EPS(LYR):-18.3696
ROE:-34.45%
ROA:2.05%
PB:1.44
PE(LYR):-3.25

Loading ...

Ashland Inc Outlook FY Adj EPS Excluding Intangibles Amortization Expense Growth Double-Digit-Plus

THOMSON REUTERS
·
Nov 05

Ashland Q4 Free Cash Flow USD 52 Million

THOMSON REUTERS
·
Nov 05

Ashland Outlook FY Adjusted Ebitda USD 400-430 Million

THOMSON REUTERS
·
Nov 05

Ashland Reports Fourth Quarter Fiscal 2025 Results and Issues Outlook for Full-Year 2026

THOMSON REUTERS
·
Nov 05

Press Release: Ashland reports fourth quarter fiscal 2025 results and issues outlook for full-year 2026

Dow Jones
·
Nov 05

Kura Oncology Reports Third Quarter 2025 Financial Results

GlobeNewswire
·
Nov 04

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 04

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SH): Multiple Studies on Golidocitinib and Birelentinib Selected for 67th ASH Annual Meeting

Stock News
·
Nov 04

Oral Presentation: Five Hematologic Malignancies Studies by Leads Biolabs to Be Featured at ASH 2025

prnewswire
·
Nov 04

Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025

GlobeNewswire
·
Nov 04

Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025

GlobeNewswire
·
Nov 04

Ascentage Pharma to Showcase Latest Clinical Study Results at ASH 2025

TIPRANKS
·
Nov 04

ASCENTAGE-B (06855) to Showcase Multiple Clinical Advances of Olverembatinib (Nerlynx®), Lisaftoclax (Lisenla®), and APG-5918 at 2025 ASH Annual Meeting, Including One Oral Presentation

Stock News
·
Nov 04

Imugene Announces Webinar on CAR T Naïve Lymphomas and ASH Presentation

TIPRANKS
·
Nov 04

Imugene’s Azer-cel Selected for Prestigious ASH Presentation

TIPRANKS
·
Nov 04

Nanjing Leads Biolabs to Present Key Research at ASH Annual Meeting

TIPRANKS
·
Nov 04

LEADS BIOLABS-B (09887): LBL-034 Clinical Study Selected as First Oral Presentation on Opening Day of 67th ASH Annual Meeting

Stock News
·
Nov 04

Legend Biotech to Showcase Key Research at ASH 2025

TIPRANKS
·
Nov 04

Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

GlobeNewswire
·
Nov 04

Active Biotech to Present Promising Tasquinimod Data at ASH 2025

TIPRANKS
·
Nov 04